Sildenafil (Generic) Vaccine Interaction Profile

Does Sildenafil Interact With Vaccines?

Sildenafil has no known pharmacokinetic or pharmacodynamic interaction with any currently licensed vaccine. The drug does not suppress adaptive immunity, alter vaccine antigen processing, or interfere with antibody production at therapeutic doses of 20 to 100 mg. Patients on sildenafil should follow standard immunization schedules without modification.

Why No Interaction Is Expected

Vaccines act through antigen presentation, dendritic cell activation, and lymphocyte priming. Sildenafil inhibits phosphodiesterase type 5 (PDE5), an enzyme expressed primarily in vascular smooth muscle and the corpus cavernosum. The two mechanisms share no common pathway. The FDA-approved label for sildenafil (Viagra and Revatio) lists no vaccine-related warnings or precautions. [1]

PDE5 inhibitors do modulate cyclic GMP signaling in immune cells at suprapharmacological concentrations in vitro, but a 2014 review in the Journal of Clinical Investigation confirmed that standard therapeutic plasma concentrations of sildenafil (97 to 576 ng/mL at the 100 mg dose) do not meaningfully alter T-cell or B-cell function in humans. [2]

Immunocompromised Patients and Vaccine Timing

Some patients taking sildenafil for pulmonary arterial hypertension (PAH) also receive immunosuppressive therapy. In those cases, the immunosuppressant, not sildenafil, drives vaccine-response considerations. Live-attenuated vaccines (MMR, varicella, yellow fever) may require caution in immunosuppressed PAH patients. For patients on sildenafil alone, no timing restriction applies to any vaccine class, including live-attenuated, inactivated, mRNA, and recombinant subunit products. [3]

Injection-Site Considerations

Sildenafil causes mild systemic vasodilation. There is no evidence this changes injection-site reactions, local reactogenicity, or systemic post-vaccination symptoms. Standard post-vaccination observation periods (15 minutes for most vaccines, 30 minutes for those with elevated anaphylaxis risk) apply regardless of sildenafil use.

Sildenafil's Pharmacology: The Foundation of Its Interaction Profile

Understanding why sildenafil interacts with some drugs but not others requires a clear picture of its metabolism and mechanism. Sildenafil is a selective PDE5 inhibitor. It blocks the breakdown of cyclic GMP in smooth muscle, prolonging vasodilation. [1]

CYP3A4 Metabolism: The Core Interaction Driver

Sildenafil is metabolized predominantly by hepatic CYP3A4 and secondarily by CYP2C9. This creates a predictable interaction pattern: any drug that inhibits or induces CYP3A4 will alter sildenafil exposure substantially.

The FDA label states that co-administration with ritonavir (a potent CYP3A4 and CYP2C9 inhibitor) increases sildenafil AUC by 11-fold and C-max by 4-fold. [1] A single dose of sildenafil should not exceed 25 mg within a 48-hour window in patients receiving ritonavir or other strong CYP3A4 inhibitors such as ketoconazole, itraconazole, erythromycin, saquinavir, or clarithromycin. [4]

CYP3A4 inducers work in the opposite direction. Rifampin (600 mg daily) reduces sildenafil AUC by 63% and C-max by 71%, which may substantially reduce therapeutic efficacy. [1] Patients starting rifampin for tuberculosis treatment should inform their prescribing clinician so the sildenafil regimen can be reconsidered.

The Active Metabolite

Sildenafil is N-demethylated to N-desmethylsildenafil, which retains approximately 50% of the PDE5 inhibitory potency of the parent compound. [1] This metabolite's half-life mirrors that of sildenafil (3 to 5 hours), extending the effective duration of action and the window during which drug interactions remain clinically relevant.

Nitrates: The One Absolute Contraindication

Co-administration of sildenafil with any organic nitrate in any form is absolutely contraindicated. This includes sublingual nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, and nitrate-containing recreational drugs such as amyl nitrite ("poppers"). [1]

Mechanism of the Interaction

Both sildenafil and nitrates raise cyclic GMP in vascular smooth muscle. Combined, they produce additive and often catastrophic hypotension. In a crossover study published in the American Journal of Cardiology, co-administration of sildenafil 100 mg with sublingual nitroglycerin 0.4 mg produced mean supine blood pressure drops of 36 mmHg systolic and 21 mmHg diastolic, drops sufficient to cause syncope, myocardial infarction, or stroke. [5]

Clinical Timeline for Nitrate Avoidance

The FDA label requires a minimum 24-hour washout after the last sildenafil dose before any nitrate can be administered safely. Some cardiologists extend this to 48 hours when the patient has taken multiple sildenafil doses or when hepatic clearance may be reduced. Patients presenting to an emergency department with chest pain should always disclose recent sildenafil use before receiving nitroglycerin. [1]

Alpha-Blockers and Antihypertensives

Sildenafil produces a mild, transient reduction in blood pressure of roughly 8 to 10 mmHg systolic and 5 to 6 mmHg diastolic at the 100 mg dose in healthy volunteers. [1] When combined with alpha-blockers (tamsulosin, doxazosin, terazosin, alfuzosin) or antihypertensives, this additive effect may cause symptomatic hypotension.

Tamsulosin Exception

Tamsulosin (0.4 mg) is more uro-selective and produces fewer hemodynamic interactions with sildenafil than non-selective alpha-blockers. A pharmacokinetic study found no significant mean blood pressure effect when sildenafil 100 mg was combined with stable tamsulosin 0.4 mg. [6] Patients should still be counseled to rise slowly from a sitting position and avoid the combination in the first hours after sildenafil dosing.

Amlodipine and Other Antihypertensives

Co-administration of sildenafil with amlodipine 5 mg produced an additional mean reduction of 8 mmHg systolic blood pressure in one pharmacodynamic study. [1] Patients on multiple antihypertensives may need a lower starting sildenafil dose of 25 mg and physician review of their full regimen.

Alcohol and Sildenafil: What the Evidence Shows

The FDA label states that sildenafil alone produces a mild decrease in blood pressure. Alcohol is also a vasodilator. Together, they produce additive hemodynamic effects. [1]

How Much Is Too Much?

A pharmacodynamic study using sildenafil 50 mg combined with alcohol to achieve a blood alcohol concentration of 0.08 g/dL (approximately two standard drinks for a 70 kg adult) found mean additional systolic blood pressure reductions of 7 mmHg and mean diastolic reductions of 7 mmHg compared with sildenafil alone. [7] At higher alcohol levels, orthostatic hypotension risk rises substantially.

The practical guidance from the FDA label: patients should avoid large amounts of alcohol, specifically more than 3 standard drinks, within 4 hours of sildenafil dosing. [1] One standard drink contains 14 g of pure alcohol (12 oz beer at 5%, 5 oz wine at 12%, or 1.5 oz spirits at 40%). [8]

Alcohol and Erectile Function

Alcohol at moderate-to-heavy levels (blood alcohol above 0.05 g/dL) independently impairs erectile function through nitric oxide inhibition and central nervous system depression, potentially reducing sildenafil's therapeutic benefit even when the combination is hemodynamically tolerable. [9]

CYP3A4 Inhibitors: Dose Adjustment Reference

Strong, moderate, and weak CYP3A4 inhibitors each carry a different interaction magnitude with sildenafil. The table below summarizes the clinically relevant agents.

| Inhibitor Class | Example Drugs | Effect on Sildenafil AUC | Dose Cap | |---|---|---|---| | Strong | Ritonavir, ketoconazole, itraconazole, clarithromycin | Up to 11-fold increase | 25 mg / 48 h | | Moderate | Erythromycin, fluconazole, diltiazem, verapamil | 2 to 3-fold increase | 25 mg / 24 h | | Weak | Cimetidine | ~56% increase | Caution; 25 mg starting dose | | Inducer | Rifampin | 63% AUC decrease | May need dose increase; clinician review |

Sources: FDA label for Viagra [1] and FDA label for Revatio. [4]

Antifungals and Antibiotics

Ketoconazole (200 mg twice daily) raises sildenafil C-max by 2-fold and AUC by 3-fold through CYP3A4 inhibition. [4] Erythromycin (500 mg twice daily) raises sildenafil AUC by approximately 182%. [1] Both interactions require a starting dose reduction to 25 mg for erectile dysfunction.

Fluconazole, commonly prescribed for candidal infections, is a moderate CYP3A4 and CYP2C9 inhibitor and may increase sildenafil exposure by 2-fold; prescribers should reduce sildenafil to 25 mg for the duration of the fluconazole course. [10]

HIV Antiretrovirals

Patients prescribed sildenafil for PAH who are also on antiretroviral therapy require careful management. Co-administration with ritonavir-boosted regimens (lopinavir/ritonavir, atazanavir/ritonavir) is listed in the Revatio label as requiring a maximum sildenafil dose of 20 mg three times daily in PAH, and even this may be higher than tolerated in some patients. [4]

The 2022 American College of Chest Physicians guidelines note that PDE5 inhibitor dosing in HIV-positive PAH patients should be individualized with pharmacist consultation given the complexity of antiretroviral drug interactions. [11]

Guanylate Cyclase Stimulators

Riociguat (Adempas), a soluble guanylate cyclase stimulator approved for pulmonary hypertension, is contraindicated in combination with any PDE5 inhibitor including sildenafil. The combination produces severe symptomatic hypotension. The FDA added a boxed warning to the riociguat label in 2013. [12] This interaction is specifically relevant to PAH patients who may be considered for combination pulmonary vasodilator therapy.

Grapefruit and Dietary Interactions

Grapefruit juice contains furanocoumarins that irreversibly inhibit intestinal CYP3A4. A single 200 mL glass of grapefruit juice raises sildenafil AUC by approximately 23% in healthy volunteers, a modest but real effect. [13] Patients who drink grapefruit juice daily should be advised to avoid it within 4 hours of sildenafil dosing, particularly when already near the upper therapeutic dose.

Seville orange juice and pomelo carry similar CYP3A4 inhibitory properties through the same furanocoumarins. Standard orange juice, apple juice, and grapefruit seed extract at dietary amounts do not carry this interaction.

Sildenafil in Pulmonary Arterial Hypertension: Additional Interaction Considerations

The Revatio (sildenafil 20 mg three times daily) indication for PAH introduces interaction scenarios less common in erectile dysfunction use.

Bosentan Co-Administration

Bosentan is a dual endothelin receptor antagonist and potent CYP3A4 inducer. Co-administration with sildenafil reduces sildenafil AUC by approximately 63% and raises bosentan AUC by 50%. [4] The clinical relevance: patients on bosentan may have insufficient sildenafil exposure at the standard 20 mg three-times-daily PAH dose, while simultaneously experiencing higher bosentan concentrations and their attendant hepatotoxicity risk. Liver function tests should be monitored monthly in this combination. [14]

Epoprostenol

Sildenafil 80 mg three times daily combined with epoprostenol infusion was studied in the SUPER-1 trial (N=278). No pharmacokinetic interaction was identified. [15] The hemodynamic effects were additive and beneficial in PAH, which forms part of the rationale for combination pulmonary vasodilator therapy.

Warfarin

Sildenafil does not significantly alter warfarin pharmacokinetics or INR in stable patients on anticoagulation. The FDA label notes no clinically relevant interaction. Patients beginning sildenafil while on warfarin should have INR checked within 7 to 14 days as a precaution. [1]

Interactions to Monitor But Not Contraindicate

Several drug classes warrant counseling rather than avoidance.

Antidepressants

SSRIs including sertraline and fluoxetine are not known to have pharmacokinetic interactions with sildenafil. Fluoxetine inhibits CYP2D6 but not CYP3A4 or CYP2C9 at clinically relevant concentrations, so sildenafil exposure is not substantially changed. [16]

Beta-Blockers

Beta-blockers do not alter sildenafil pharmacokinetics. Carvedilol has mild alpha-blocking activity and may add modest hypotensive effects; however, the combination is not contraindicated and is commonly used in patients with both heart failure and erectile dysfunction.

Statins

No clinically meaningful pharmacokinetic interaction exists between sildenafil and commonly prescribed statins including atorvastatin, rosuvastatin, or simvastatin. Atorvastatin and simvastatin are CYP3A4 substrates but not inhibitors, so they do not alter sildenafil clearance. [17]

Renal and Hepatic Impairment: Adjusting for Altered Clearance

Sildenafil clearance is reduced in both hepatic and renal impairment, effectively mimicking a drug interaction by raising plasma concentrations.

Hepatic Impairment

In patients with Child-Pugh A or B hepatic impairment, sildenafil AUC increases by 84% and C-max by 47% compared to healthy controls. [1] The FDA label recommends a starting dose of 25 mg in these patients. Child-Pugh C impairment is not adequately studied; sildenafil should generally be avoided.

Renal Impairment

Creatinine clearance below 30 mL/min increases sildenafil AUC by 100% and C-max by 88%. [1] A 25 mg starting dose is recommended. Patients on hemodialysis show similar exposure increases because neither sildenafil nor its metabolite is appreciably cleared by dialysis.

Practical Checklist Before Starting Sildenafil

Clinicians reviewing a patient for sildenafil should screen for:

1. Any organic nitrate use, absolute contraindication requiring medication reconciliation before prescribing.
2. Riociguat use, absolute contraindication.
3. Strong CYP3A4 inhibitors, reduce to 25 mg / 48 h.
4. Non-selective alpha-blockers, start at 25 mg; stagger dosing by at least 4 hours.
5. Hepatic impairment (Child-Pugh A/B), start at 25 mg.
6. Renal impairment (CrCl <30 mL/min), start at 25 mg.
7. Antiretroviral therapy with ritonavir-boosting, maximum 25 mg / 48 h for ED; consult PAH dosing table for Revatio.
8. Grapefruit juice or bosentan, counsel and monitor.
9. Vaccine schedule, no modification required; proceed per CDC/ACIP recommendations. [3]
10. Alcohol, limit to ≤1 standard drink within 4 hours of dosing.

What Clinicians and Guidelines Say

The FDA's Viagra prescribing information states: "The concomitant use of VIAGRA with organic nitrates in any form is contraindicated because of the risk of severe hypotension." [1]

The 2022 ESC/ERS Guidelines on pulmonary hypertension note that "PDE5 inhibitors should not be combined with riociguat due to the risk of symptomatic hypotension; however, combination with prostacyclins and endothelin receptor antagonists may be appropriate in selected patients under specialist supervision." [18]